Alexandre Sadate1, Bob V Occean2, Jean-Paul Beregi3, Aymeric Hamard3, Takieddine Addala3, Hélène de Forges3, Pascale Fabbro-Peray2, Julien Frandon3. 1. Department of Radiology and Medical Imaging, CHU Nîmes, Univ. Montpellier, EA2415, Nîmes, France. Electronic address: alexandre.sadate@chu-nimes.fr. 2. Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology (BESPIM), CHU Nîmes, Univ. Montpellier, Nîmes, France. 3. Department of Radiology and Medical Imaging, CHU Nîmes, Univ. Montpellier, EA2415, Nîmes, France.
Abstract
INTRODUCTION: Lung cancer (LC) has the highest cancer mortality worldwide with poor prognosis. Screening with low-dose computed tomography (LDCT) in populations highly exposed to tobacco has been proposed to improve LC prognosis. Our objective was to perform a systematic review and meta-analysis to evaluate the efficacy of screening by LDCT compared with any other intervention in populations who reported tobacco consumption for more than 15 years on LC and overall mortality. METHODS: We searched randomised controlled trials (RCTs) studying screening by LDCT compared with any other intervention in a population who reported an average smoking history greater than 15 pack-years from inception until the 19th February 2018 using Medline and Cochrane Library databases. Publication selection and data extraction were made independently by two double-blind reviewers. RESULTS: Seven RCTs were included in the meta-analysis which corresponds to 84,558 participants. A significant relative reduction of LC-specific mortality of 17% (risk ratio [RR] = 0.83, 95% confidence interval [CI]: 0.76-0.91) and a relative reduction of overall mortality of 4% (RR = 0.96, 95% CI: 0.92-1.00) was observed in the screening group compared with the control group. CONCLUSION: In populations highly exposed to tobacco, screening by LDCT reduces lung cancer mortality.
INTRODUCTION:Lung cancer (LC) has the highest cancer mortality worldwide with poor prognosis. Screening with low-dose computed tomography (LDCT) in populations highly exposed to tobacco has been proposed to improve LC prognosis. Our objective was to perform a systematic review and meta-analysis to evaluate the efficacy of screening by LDCT compared with any other intervention in populations who reported tobacco consumption for more than 15 years on LC and overall mortality. METHODS: We searched randomised controlled trials (RCTs) studying screening by LDCT compared with any other intervention in a population who reported an average smoking history greater than 15 pack-years from inception until the 19th February 2018 using Medline and Cochrane Library databases. Publication selection and data extraction were made independently by two double-blind reviewers. RESULTS: Seven RCTs were included in the meta-analysis which corresponds to 84,558 participants. A significant relative reduction of LC-specific mortality of 17% (risk ratio [RR] = 0.83, 95% confidence interval [CI]: 0.76-0.91) and a relative reduction of overall mortality of 4% (RR = 0.96, 95% CI: 0.92-1.00) was observed in the screening group compared with the control group. CONCLUSION: In populations highly exposed to tobacco, screening by LDCT reduces lung cancer mortality.
Authors: Asha Bonney; Reem Malouf; Corynne Marchal; David Manners; Kwun M Fong; Henry M Marshall; Louis B Irving; Renée Manser Journal: Cochrane Database Syst Rev Date: 2022-08-03
Authors: Hao Chen; Yan Jiang; Keyi Jia; Kaixuan Zhang; Natsumi Matsuura; Jin Yong Jeong; Bo Su; Xiao Zhou Journal: Transl Lung Cancer Res Date: 2021-10